These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 31593801)

  • 1. A novel FTY720 analogue targets SET-PP2A interaction and inhibits growth of acute myeloid leukemia cells without inducing cardiac toxicity.
    Vicente C; Arriazu E; Martínez-Balsalobre E; Peris I; Marcotegui N; García-Ramírez P; Pippa R; Rabal O; Oyarzábal J; Guruceaga E; Prósper F; Mateos MC; Cayuela ML; Odero MD
    Cancer Lett; 2020 Jan; 468():1-13. PubMed ID: 31593801
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A new regulatory mechanism of protein phosphatase 2A activity via SET in acute myeloid leukemia.
    Arriazu E; Vicente C; Pippa R; Peris I; Martínez-Balsalobre E; García-Ramírez P; Marcotegui N; Igea A; Alignani D; Rifón J; Mateos MC; Cayuela ML; Nebreda AR; Odero MD
    Blood Cancer J; 2020 Jan; 10(1):3. PubMed ID: 31913266
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PP2A impaired activity is a common event in acute myeloid leukemia and its activation by forskolin has a potent anti-leukemic effect.
    Cristóbal I; Garcia-Orti L; Cirauqui C; Alonso MM; Calasanz MJ; Odero MD
    Leukemia; 2011 Apr; 25(4):606-14. PubMed ID: 21233840
    [TBL] [Abstract][Full Text] [Related]  

  • 4. FTY720 induces apoptosis of M2 subtype acute myeloid leukemia cells by targeting sphingolipid metabolism and increasing endogenous ceramide levels.
    Chen L; Luo LF; Lu J; Li L; Liu YF; Wang J; Liu H; Song H; Jiang H; Chen SJ; Luo C; Li KK
    PLoS One; 2014; 9(7):e103033. PubMed ID: 25050888
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Activation of protein phosphatase 2A in FLT3+ acute myeloid leukemia cells enhances the cytotoxicity of FLT3 tyrosine kinase inhibitors.
    Smith AM; Dun MD; Lee EM; Harrison C; Kahl R; Flanagan H; Panicker N; Mashkani B; Don AS; Morris J; Toop H; Lock RB; Powell JA; Thomas D; Guthridge MA; Moore A; Ashman LK; Skelding KA; Enjeti A; Verrills NM
    Oncotarget; 2016 Jul; 7(30):47465-47478. PubMed ID: 27329844
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antagonistic activities of the immunomodulator and PP2A-activating drug FTY720 (Fingolimod, Gilenya) in Jak2-driven hematologic malignancies.
    Oaks JJ; Santhanam R; Walker CJ; Roof S; Harb JG; Ferenchak G; Eisfeld AK; Van Brocklyn JR; Briesewitz R; Saddoughi SA; Nagata K; Bittman R; Caligiuri MA; Abdel-Wahab O; Levine R; Arlinghaus RB; Quintas-Cardama A; Goldman JM; Apperley J; Reid A; Milojkovic D; Ziolo MT; Marcucci G; Ogretmen B; Neviani P; Perrotti D
    Blood; 2013 Sep; 122(11):1923-34. PubMed ID: 23926298
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Influence of PP2A activator on proliferation of HL-60 cells and analysis of PP2A activity changes in patients with acute myeloid leukemia].
    Yang Y; Li XQ; Huang Q; Huang SA
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2011 Jun; 19(3):594-7. PubMed ID: 21729530
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sphingosine analogue drug FTY720 targets I2PP2A/SET and mediates lung tumour suppression via activation of PP2A-RIPK1-dependent necroptosis.
    Saddoughi SA; Gencer S; Peterson YK; Ward KE; Mukhopadhyay A; Oaks J; Bielawski J; Szulc ZM; Thomas RJ; Selvam SP; Senkal CE; Garrett-Mayer E; De Palma RM; Fedarovich D; Liu A; Habib AA; Stahelin RV; Perrotti D; Ogretmen B
    EMBO Mol Med; 2013 Jan; 5(1):105-21. PubMed ID: 23180565
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reactivating PP2A by FTY720 as a novel therapy for AML with C-KIT tyrosine kinase domain mutation.
    Yang Y; Huang Q; Lu Y; Li X; Huang S
    J Cell Biochem; 2012 Apr; 113(4):1314-22. PubMed ID: 22109829
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PP2A inhibition is a common event in colorectal cancer and its restoration using FTY720 shows promising therapeutic potential.
    Cristóbal I; Manso R; Rincón R; Caramés C; Senin C; Borrero A; Martínez-Useros J; Rodriguez M; Zazo S; Aguilera O; Madoz-Gúrpide J; Rojo F; García-Foncillas J
    Mol Cancer Ther; 2014 Apr; 13(4):938-47. PubMed ID: 24448818
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lipid Nanosystems Enhance the Bioavailability and the Therapeutic Efficacy of FTY720 in Acute Myeloid Leukemia.
    Estella-Hermoso de Mendoza A; Castello-Cros R; Imbuluzqueta E; Cirauqui C; Pippa R; Odero MD; Blanco-Prieto MJ
    J Biomed Nanotechnol; 2015 Apr; 11(4):691-701. PubMed ID: 26310075
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synergic effect of OP449 and FTY720 on oral squamous cell carcinoma.
    Goto RN; Sobral LM; Stringhetta-Padovani K; Garcia CB; da Silva G; Vitek MP; Leopoldino AM
    Eur J Pharmacol; 2020 Sep; 882():173268. PubMed ID: 32569675
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Overexpression of PP2A inhibitor SET oncoprotein is associated with tumor progression and poor prognosis in human non-small cell lung cancer.
    Liu H; Gu Y; Wang H; Yin J; Zheng G; Zhang Z; Lu M; Wang C; He Z
    Oncotarget; 2015 Jun; 6(17):14913-25. PubMed ID: 25945834
    [TBL] [Abstract][Full Text] [Related]  

  • 14. FTY720 inhibits mesothelioma growth in vitro and in a syngeneic mouse model.
    Szymiczek A; Pastorino S; Larson D; Tanji M; Pellegrini L; Xue J; Li S; Giorgi C; Pinton P; Takinishi Y; Pass HI; Furuya H; Gaudino G; Napolitano A; Carbone M; Yang H
    J Transl Med; 2017 Mar; 15(1):58. PubMed ID: 28298211
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PP2A activation alone and in combination with cisplatin decreases cell growth and tumor formation in human HuH6 hepatoblastoma cells.
    Stafman LL; Williams AP; Marayati R; Aye JM; Stewart JE; Mroczek-Musulman E; Beierle EA
    PLoS One; 2019; 14(4):e0214469. PubMed ID: 30969990
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of FTY720 on the SET-PP2A complex in acute myeloid leukemia; SET binding drugs have antagonistic activity.
    Pippa R; Dominguez A; Christensen DJ; Moreno-Miralles I; Blanco-Prieto MJ; Vitek MP; Odero MD
    Leukemia; 2014 Sep; 28(9):1915-8. PubMed ID: 24781014
    [No Abstract]   [Full Text] [Related]  

  • 17. SET-PP2A complex as a new therapeutic target in KMT2A (MLL) rearranged AML.
    Di Mambro A; Arroyo-Berdugo Y; Fioretti T; Randles M; Cozzuto L; Rajeeve V; Cevenini A; Austin MJ; Esposito G; Ponomarenko J; Lucas CM; Cutillas P; Gribben J; Williams O; Calle Y; Patel B; Esposito MT
    Oncogene; 2023 Dec; 42(50):3670-3683. PubMed ID: 37891368
    [TBL] [Abstract][Full Text] [Related]  

  • 18. FTY720 demonstrates promising preclinical activity for chronic lymphocytic leukemia and lymphoblastic leukemia/lymphoma.
    Liu Q; Zhao X; Frissora F; Ma Y; Santhanam R; Jarjoura D; Lehman A; Perrotti D; Chen CS; Dalton JT; Muthusamy N; Byrd JC
    Blood; 2008 Jan; 111(1):275-84. PubMed ID: 17761520
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Essential requirement for PP2A inhibition by the oncogenic receptor c-KIT suggests PP2A reactivation as a strategy to treat c-KIT+ cancers.
    Roberts KG; Smith AM; McDougall F; Carpenter H; Horan M; Neviani P; Powell JA; Thomas D; Guthridge MA; Perrotti D; Sim AT; Ashman LK; Verrills NM
    Cancer Res; 2010 Jul; 70(13):5438-47. PubMed ID: 20551067
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel B55α-PP2A mutations in AML promote AKT T308 phosphorylation and sensitivity to AKT inhibitor-induced growth arrest.
    Shouse G; de Necochea-Campion R; Mirshahidi S; Liu X; Chen CS
    Oncotarget; 2016 Sep; 7(38):61081-61092. PubMed ID: 27531894
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.